How I diagnose high-grade B-cell lymphoma
American Journal of Clinical Pathology · 2025
DOI: 10.1093/ajcp/aqae158 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Clinical Pathology, 2025. Verfasst von Erika M Moore und 1 weiteren Autor:innen. Beteiligte Einrichtung: University of Pittsburgh School of Medicine, Pittsburgh, PA, US. Hauptthemen laut MEDLINE: Lymphoma, B-Cell. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 80 Literaturangaben.
Abstract (Originalsprache)
Objectives
High-grade B-cell lymphoma (HGBL), introduced in the 2016 World Health Organization (WHO) revised fourth edition classification, included cases defined by MYC and BCL2 and/or BCL6 rearrangements or by high-grade morphology. Diagnostic criteria and nomenclature for these lymphomas were refined in the 2022 WHO fifth edition (WHO-5) classification and International Consensus Classification (ICC). This review describes our approach to the diagnosis of HGBL.
Methods
Two cases are presented illustrating how we diagnose HGBL, including 1 case harboring MYC and BCL6 rearrangements and a second showing TdT expression in an HGBL with MYC and BCL2 rearrangements. The ways in which these cases are distinguished from other lymphomas with high-grade features and the appropriate nomenclature using WHO-5 and ICC classifications are emphasized.
Results
An HGBL diagnosis requires integration of morphology, immunophenotype, and genetics and exclusion of other lymphomas with high-grade morphology, including Burkitt lymphoma, B-lymphoblastic leukemia/lymphoma (B-LBL/ALL), and blastoid mantle cell lymphoma. A diagnosis of HGBL/large B-cell lymphoma with 11q aberration should also be considered in certain patient populations.
Conclusions
High-grade B-cell lymphomas are subclassified based on morphologic and genetic features. There are differences in the nomenclature and definition of these lymphomas in the WHO-5 and ICC classifications. Distinguishing HGBLs from other mature B-cell lymphomas and B-LBL/ALL is critical so that patients receive appropriate treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Pittsburgh School of Medicine, Pittsburgh, PA, US.
- Mayo Clinic Arizona, Phoenix, AZ, US.
ORCID-Profile: Erika M Moore, Sarah E Gibson
Zitieren
APA
Moore, E. M., & Gibson, S. E. (2025). How I diagnose high-grade B-cell lymphoma. American Journal of Clinical Pathology. https://doi.org/10.1093/ajcp/aqae158
Vancouver
Moore EM, Gibson SE. How I diagnose high-grade B-cell lymphoma. American Journal of Clinical Pathology. 2025. doi:10.1093/ajcp/aqae158
BibTeX
@article{Moore2025,
author = {Moore, Erika M and Gibson, Sarah E},
title = {How I diagnose high-grade B-cell lymphoma},
journal = {American Journal of Clinical Pathology},
year = {2025},
doi = {10.1093/ajcp/aqae158}
}
EUVIMED